Summit Therapeutics (SMMT) Fair Value & DCF
Score
SMMT fair value $11.87. Price $15.07. Price is 27% above fair value.
Worked example
Cash-flow value. Starting free cash flow is $0.00 a share. Years 1 to 5 grow at 0.00%. Years 6 to 10 fade that rate in a straight line to 3% terminal growth. The discount rate is 10.00%. It is beta-adjusted and capped at 12%. The cash-flow value is $0.19 a share.
Earnings value. Next-twelve-months earnings per share of $0.82 times 28.54 is $23.55. The peer group is Biotechnology, 11 companies worth at least $10 billion. This stock has no 10-year median P/E, so the peer median of 28.5 is kept between 8 and 30, which is 28.54.
Fair value is the average of the two, $11.87. The price is $15.07, which is 27.0% above fair value.